Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2018-03-21 Capital/Financing Update
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Capital Raising 1 page 26.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from BARD1 Life Sciences Limited regarding a capital raising event through a share placement to sophisticated and professional investors. It details the amount to be raised, the number of shares to be issued, the issue price, and the intended use of funds. There is no financial report, earnings data, or detailed financial statements included. The document is focused on informing the market about the financing activity, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2018-03-21 English
Corporate Presentation 21 pages 936.2KB
Investor Presentation Classification · 95% confidence The document is titled 'BARD1 RELEASES CORPORATE PRESENTATION' and contains detailed information about the company's technology, pipeline, market opportunities, and strategy. It is a presentation aimed at shareholders and investors, providing an overview of the company and its business. There are no financial statements or detailed financial performance data typical of annual or interim reports. The document is not an announcement of a report publication but the actual presentation content itself. Therefore, it fits the definition of an Investor Presentation (IP).
2018-03-21 English
Israeli Patent Issued in Bard1 Core Patent Family 2 pages 145.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the issuance of an Israeli patent related to the company's core patent family for a cancer diagnostic test. It discusses the patent details, patent family status, and the company's intellectual property portfolio. There is no financial data, no regulatory filing, no report publication announcement, no management or board changes, no earnings or interim report, no call transcript, no voting results, no dividend information, no capital or financing update, and no legal proceedings. The content is primarily an announcement about intellectual property and patent status, which does not fit into any of the specific financial or regulatory report categories. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2018-03-20 English
Trading Halt 2 pages 100.4KB
Capital/Financing Update Classification · 95% confidence The document is a market release dated 20 March 2018 from BARD1 Life Sciences Limited, requesting a trading halt on its securities pending the release of an announcement regarding a capital raising. The text explicitly states the reason for the trading halt is the intention to make an announcement about a capital raising. There is no actual financial data or detailed report content in the document; it is a regulatory announcement about a trading halt related to upcoming capital raising news. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). This document is not the announcement of the capital raising itself but the trading halt request preceding it, which is typically classified under Capital/Financing Update as it relates directly to financing activities. The document length is short and does not contain financial statements or detailed analysis, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing (RNS) because it is a specific market release about trading halt for capital raising. Therefore, the best fit is Capital/Financing Update (CAP).
2018-03-19 English
Additional BARD1 Ovarian Test Results 2 pages 226.3KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing additional positive results from a follow-on study of the BARD1-Ovarian test, a diagnostic test for early detection of ovarian cancer. It includes study results, sensitivity and specificity data, and commentary from company executives. The document is an announcement of scientific study results and product development progress, not a financial report, regulatory filing, or management discussion. It does not contain financial statements, earnings data, or regulatory compliance information. It is also not a presentation, proxy, or voting result. The content is consistent with a Capital/Financing Update (CAP) or a Regulatory Filing (RNS) but since it is primarily a scientific and product development announcement related to the company's diagnostic test progress and not a financing or capital structure update, the best fit is Regulatory Filings (RNS) as a general announcement category for miscellaneous filings that do not fit other categories.
2018-03-05 English
Half Yearly Report and Accounts 19 pages 2.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D For the Half Year ended 31 December 2017' and is from Bard1 Life Sciences Limited. It contains detailed financial information for the half-year period ending 31 December 2017, including a Directors' Report, Directors' Declaration, Auditor's Independence Declaration, Consolidated Statement of Comprehensive Income, Statement of Financial Position, Cash Flow, Changes in Equity, Notes to Financial Statements, and an Independent Auditor's Review Report. The document includes actual financial data, operational review, capital raising details, and audit review information. The presence of comprehensive financial statements and notes for a half-year period clearly identifies this as an Interim / Quarterly Report. The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2018
2018-02-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.